

Certificate of Analysis

PAK2, active

(Recombinant enzyme expressed in *E.coli* cells)

Item # 14-481, 14-481-K, 14-481M

Parent Lot # 1685379

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: C-terminal and N-terminal 6His-tagged and N-terminal T7 tagged, recombinant, human PAK2 amino acids 3–end, expressed in *E.coli* cells. Purified using Ni²⁺/NTA-agarose. Purity 71.6% by SDS-PAGE and Coomassie blue staining. MW = 62.8kDa.

Formulation: 4.339mg/ml of enzyme in 50mM Tris/HCl pH 7.5, 150mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.


Specific Activity (Parent lot# 1685379): 3216U/mg, where one unit of PAK2, active activity is defined as 1nmol phosphate incorporated into 30μM Long S6 peptide per minute at 30°C with a final ATP concentration of 100μM.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.6–2.6ng of this lot of enzyme phosphorylated 30μM Long S6 peptide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as PAK2 with the translated sequence listed on page three



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Long S6 substrate peptide:** Use at a final assay concentration of 30 μ M. Make up a 300 μ M stock. Add 2.5 μ l of stock per assay point.
3. **PAK2, active:** Dilute in 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.6–2.6ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of reaction buffer per assay to wells.
2. Add 2.5 μ l of **Long S6 substrate peptide**.
3. Add **2.5 μ l (0.6–2.6ng) PAK2, active**.
4. Add 5 μ l of dH₂O.
5. Add 10 μ l of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

PAK2 Sequence Information

<u>Protein</u>	Human PAK2
<u>Tags</u>	N-terminal and C-terminal 6His-tagged and N-terminal T7 tagged
<u>Native sequence</u>	D37 of the recombinant protein is equivalent to D3 of human PAK2
<u>Accession number</u>	GenBank NM_U24153. The recombinant protein contains the amino acid substitutions L150F, P225T, V383I and ΔA339 with respect to this accession number. L150F, P225T and ΔA339 are reported in GenBank NM_U25975. The residue co ordinates in the native sequence have been given.

Recombinant PAK2 amino acid sequence:

```

1  MGSSHHHHHH  SSGLVPRGSH  MASMTGGQQM  GRGSMLDNGE  LEDKPPAPPV  RMSSTIFSTG
61  GKDPLSANHS  LKPLPSVPEE  KKPRHKIISI  FSGTEKGSKK  KEKERPEISP  PSDFEHTIHV
121  GFDAVTGEFT  GMPEQWARLL  QTSNITKLEQ  KKNPQAVLDV  LKFYDSNTVK  QKYLSTFPPE
181  KDGFPSGTPA  LNAKGTEAPA  VVTEEDDDE  ETAPPVIAPR  PDHTKSIYTR  SVIDPVPAV
241  GDSHVDGAAK  SLDKQKKKTK  MTDEEIMEKL  RTIVSIGDPK  KKYTRYEKIG  QGASGTVFTA
301  TDVALGQEVA  IKQINLQKQP  KELIINEIL  VMKELKNPNI  VNFLDSYLVG  DELFVVM EYL
361  AGGSLTDVVT  ETCMDEAQIA  AVCRECLQAL  EFLHANQVIH  RDIKSDNVLL  GMEGSIKLT
421  FGCAQITPE  QSKRSTMVGT  PYWMAPEVVT  RKAYGPKVDI  WSLGIMAIEM  VEGEPYLYNE
481  NPLRALYLIA  TNGTPELQNP  EKLSPIFRDF  LNRCLMDVDE  KRGSAKELLQ  HPFLKLAKPL
541  SSLTPLIMAA  KEAMKSNRLE  HHHHHH

```

Recombinant PAK2 nucleotide sequence:

```

1  atgggcagca  gccatcatca  tcatcatcac  agcagcggcc  tgggtgccgcg  cggcagccat
61  atggctagca  tgactggtgg  acagcaaata  ggtcgcggat  ccatgctcga  taacggagaa
121  ctggaagata  agcctccagc  acctcctgtg  cgaatgagca  gcaccatctt  tagcactgga
181  ggcaaagacc  ctttgtcagc  caatcacagt  ttgaaacctt  tgccctctgt  tccagaagag
241  aaaaagccca  ggcataaaat  catctccata  ttctcaggca  cagagaaaag  aagtaaaaag
301  aaagaaaagg  aacggccaga  aatttctcct  ccatctgatt  ttgagcacac  catccatgtt
361  ggctttgatg  ctgttactgg  agaattcact  ggcatgccag  aacagtgggc  tcgattacta
421  cagacctcca  atatcaccaa  actagagcaa  aagaagaatc  ctcaggctgt  gctggatgtc
481  ctaaagtctt  acgactccaa  cacagtgaag  cagaaatatc  tgagctttac  tcctcctgag
541  aaagatggct  ttcttcttgg  aacaccagca  ctgaatgcca  agggaacaga  agcaccgcga
601  gtatgtacag  aggaggagga  tgatgtgaa  gagactgctc  ctcccgttat  tgccccgcga
661  ccggatcata  cgaaatcaat  ttacacacgg  tctgtaatgt  accctgttcc  tgcaccagtt
721  ggtgattcac  atgttgatgg  tgctgccaag  tcttttagaca  aacagaaaaa  gaagactaag
781  atgacagatg  aagagattat  ggagaaatta  agaactatcg  tgagcatagg  tgaccctaag
841  aaaaaatata  caagatatga  aaaaattgga  caaggggctt  ctggtacagt  tttcactgct
901  actgacgttg  cactgggaca  ggaggttgct  atcaaacaaa  ttaatttaca  gaaacagcca
961  aagaaggaac  tgatcattaa  cgagattctg  gtgatgaaag  aattgaaaaa  tcccaacatc
1021  gttaaactttt  tggacagtta  cctggtagga  gatgaattgt  ttgtgggtcat  ggaatacctt
1081  gctgggggggt  cactcactga  tgtggtaaca  gaaacgtgca  tggatgaagc  acagattgct
1141  gctgtatgca  gagagtgttt  acaggcattg  gagtttttac  atgctaataca  agtgatccac
1201  agagacatca  aaagtgacaa  tgtacttttg  ggaatggaag  gatctattaa  gctcactgac
1261  tttggtttct  gtgccagat  caccctgag  cagagcaaac  gcagtaccat  ggtcggaaag
1321  ccatactgga  tggcaccaga  ggtggttaca  cggaaagctt  atggccctaa  agtcgacata
1381  tggctctctgg  gtatcatggc  tattgagatg  gtagaaggag  agcctccata  cctcaatgaa
1441  aatcccttga  gggccttgta  cctaatagca  actaatggaa  cccagaact  tcagaatcca
1501  gagaaacttt  ccccaatatt  tcgggatttc  ttaaactgat  gtttggaat  ggatgtggaa
1561  aaaaggggtt  cagccaaaga  attattacag  catcctttcc  tgaaactggc  caaacgttta

```

Certificate of Analysis

1621 tctagcttga caccactgat catggcagct aaagaagcaa tgaagagtaa ccgtctcgag
1681 caccaccacc accaccactg a

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services.